Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.


Over the past two decades, therapeutics for diabetes have evolved from drugs with known heart failure risk to classes with potential benefit for patients with heart failure. As many as 25 to 35 % of patients with heart failure carry a diagnosis of type 2 diabetes mellitus. Therefore, newer drug classes including dipeptidyl peptidase 4 (DPP-4) inhibitors… (More)
DOI: 10.1007/s11897-016-0291-y


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics